Shots:
Pfizer has reported P-II (FOURLIGHT-1) trial data assessing atirmociclib + fulvestrant vs fulvestrant or everolimus plus exemestane in 264 pts with HR+, HER2- advanced or metastatic breast cancer who had received prior CDK 4/6 inhibitor-based treatment
Trial met its 1EP, showing improved PFS as assessed by the investigator, with benefit consistent across all subgroups. OS…
